[A19-47] Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04
Last updated 04.07.2019
Project no.:
A19-47
Commission:
Commission awarded on 27.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Insomnia in children and adolescents with Autism Spectrum Disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
Conclusion of dossier assessment A19-04 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-04 | Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.